Protease Inhibitors for HIV Infection
Authors: John G. Bartlett
Journal: Annals of Internal Medicine (1996)

Editorials15 June 1996Protease Inhibitors for HIV InfectionJohn G. Bartlett, MDJohn G. Bartlett, MDJohns Hopkins University School of Medicine, Baltimore, MD 21205..Author, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-124-12-199606150-00011 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Antiviral therapy directed against human immunodeficiency virus type 1 (HIV-1) is now approaching its 10-year anniversary. The initial clinical trial of zidovudine was completed in September 1986, and, with expedited review, zidovudine was approved by the Food and Drug Administration (FDA) early in 1987 [1]. The ensuing years have seen the introduction of many other nucleoside analogues that inhibit reverse transcriptase, including (in order of their approval by the FDA) didanosine, zalcitabine, stavudine, and lamivudine. All of these drugs inhibit HIV in vitro, all are associated with a decrease in viral RNA concentrations in serum, all are associated with an ...References1. Fischl MA, Richman DD, Grieco MH, Gottlieb MS, Volberding PA, Laskin OL, et al. The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. N Engl J Med. 1987; 317:185-91. Google Scholar2. Ho DD, Neumann AU, Perelson AS, Chen W, Leonard JM, Markowitz M, et al. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature. 1995; 373:123-6. Google Scholar3. Wei X, Ghosh SK, Taylor ME, Johnson VA, Emini EA, Deutsch P, et al. Viral dynamics in human immunodeficiency virus type 1 infection. Nature. 1995; 373:117-22. Google Scholar4. Sande MA, Carpenter CC, Cobbs CG, Holmes KK, Sanford JP. Antiretroviral therapy for adult HIV-infected patients. Recommendations from a state-of-the-art conference. National Institute of Allergy and Infectious Diseases State-of-the-Art Panel on Anti-Retroviral Therapy for Adult HIV-Infected Patients. JAMA. 1993; 270:2583-9. Google Scholar5. Ho DD. Time to hit HIV, early and hard [Editorial]. N Engl J Med. 1995; 333:450-1. Google Scholar6. Roberts NA, Martin JA, Kinchington D, Broadhurst AV, Craig JC, Duncan IB, et al. Rational design of peptide-based HIV proteinase inhibitors. Science. 1990; 248:358-61. Google Scholar7. Erickson JR, Neidhart DJ, Van Drie J, Kempf DJ, Wang XC, Norbeck DW, et al. Design, activity, and 2.8 A crystal structure of a C2 symmetric inhibitor complexed to HIV-1 protease. Science. 1990; 249:527-33. Google Scholar8. Lam PY, Jadhav PK, Eyermann CJ, Hodge CN, Ru Y, Bacheler LT, et al. Rational design of potent, bioavailable, nonpeptide cyclic ureas as HIV protease inhibitors. Science. 1994; 263:380-4. Google Scholar9. Kitchen VS, Skinner C, Ariyoshi K, Lane EA, Duncan IB, Burckhardt J, et al. Safety and activity of saquinavir in HIV infection. Lancet. 1995; 345:952-5. Google Scholar10. Schapiro JM, Winters MA, Stewart F, Efron B, Norris J, Kozal MJ, Merigan TC. The effect of high-dose saquinavir on viral load and CD4+ T-cell counts in HIV-infected patients. Ann Intern Med. 1996; 124:1039-50. Google Scholar11. Kempf D, Marsh K, Denissen J, Kumar G, Rodrigues D, McDonald E, et al. Coadministration with ritonavir enhances the plasma levels of HIV protease inhibitors by inhibition of cytochrome P450 [Abstract]. Third Conference on Retroviruses and Opportunistic Infections. IDSA, NIH and CDC, 28 January-1 February 1996, Washington, DC. Google Scholar12. Markowitz M, Saag M, Powderly WG, Hurley AM, Hsu A, Valdes JM, et al. A preliminary study of ritonavir, an inhibitor of HIV-1 protease, to treat HIV-1 infection. N Engl J Med. 1995; 333:1534-9. Google Scholar13. Danner SA, Carr A, Leonard JM, Lehman LM, Gudiol F, Gonzales J, et al. A short-term study of the safety, pharmacokinetics, and efficacy of ritonavir, an inhibitor of HIV-1 protease. European-Australian Collaborative Ritonavir Study Group. N Engl J Med. 1995; 333:1528-33. Google Scholar14. Gulick R, Mellors J, Havlir D, Eron J, Gonzalez C, McMahon E, et al. Potent and sustained antiretroviral activity of indinavir in combination with zidovudine and lamivudine [Abstract]. Third Conference on Retroviruses and Opportunistic Infections. IDSA, NIH and CDC, 28 January-1 February 1996, Washington, DC. Google Scholar15. Massari F, Conant M, Mellors J, Steigbigel R, Mildvan D, Greenberg R, et al. A phase II open-label, randomized study of the triple combination of indinavir, zidovudine and didanosine versus indinavir alone and zidovudine/didanosine alone and zidovudine/didanosine in antiretroviral naive patients [Abstract]. Third Conference on Retroviruses and Opportunistic Infections, IDSA, NIH and CDC, 28 January-1 February 1996, Washington, DC. Google Scholar16. Cameron B, Heath-Chiozzi M, Kravei S, Mills R, Potthoff A, Henry D, et al. Prolongation of life and prevention of AIDS in advanced HIV immunodeficiency with ritonavir [Abstract]. Third Conference on Retroviruses and Opportunistic Infections, IDSA, NIH and CDC, 28 January-1 February 1996, Washington, DC. Google Scholar17. Markowitz M, Mo H, Kempf DJ, Norbeck DW, Bhat TN, Erickson JW, et al. Selection and analysis of human immunodeficiency virus type 1 variants with increased resistance to ABT-538, a novel protease inhibitor. J Virol. 1995; 69:701-6. Google Scholar18. Condra JH, Schleif WA, Blahy OM, Gabryelski LJ, Graham DJ, Quintero JC, et al. In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors. Nature. 1995; 374:569-71. Google Scholar Author, Article, and Disclosure InformationAffiliations: Johns Hopkins University School of Medicine, Baltimore, MD 21205..Corresponding Author: John G. Bartlett, MD, Ross 1159, 720 Rutland Avenue, Baltimore, MD 20205. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoThe Effect of High-Dose Saquinavir on Viral Load and CD4+ T-Cell Counts in HIV-Infected Patients Jonathan M. Schapiro , Mark A. Winters , Fran Stewart , Bradley Efron , Jane Norris , Michael J. Kozal , and Thomas C. Merigan Metrics Cited ByAIDS and COVID: A tale of two pandemics and the role of statisticiansLongitudinal trends in base antiretroviral therapy utilization for human immunodeficiency virus from 2000 to 2016Drug-Induced Kidney Stones and Crystalline Nephropathy: Pathophysiology, Prevention and TreatmentHIV-ASSOCIATED RETINOPATHY IN THE HAART ERAEvolution of HIV-1-related conjunctival molluscum contagiosum under HAART: report of a bilaterally manifesting case and literature reviewCare of the Adult Patient with HIV InfectionMethamphetamine abuse as a barrier to HIV medication adherence among gay and bisexual menTopical cidofovir for the treatment of dermatologic conditions: verruca, condyloma, intraepithelial neoplasia, herpes simplex and its potential use in smallpoxThe Changing Clinical Spectrum of Human Immunodeficiency Virus (HIV)-Related Oral Lesions in 1,000 Consecutive PatientsResponse to Two Consecutive Protease Inhibitor Combination Therapy Regimens in a Cohort of HIV-1-infected ChildrenAntiretroviral Prescribing Patterns in the Texas Prison SystemMetabolic Disorders Among HIV-Infected Patients Treated With Protease Inhibitors: A ReviewMetabolic Disorders Among HIV-Infected Patients Treated With Protease Inhibitors: A ReviewRenal toxicity of protease inhibitorsEffect of Highly Active Antiretroviral Therapy on the Incidence of HIV-Related Cytomegalovirus Retinitis and Retinal DetachmentSaving Lives, Saving Money: Shepherding the Role of TechnologyDesign of small peptidomimetic HIV-1 protease inhibitors and prodrug formsEffects of HIV counseling and testing on sexual risk behavior: a meta-analytic review of published research, 1985-1997.Irreversible Inhibition of Human Immunodeficiency Virus Type 1 Integrase by Dicaffeoylquinic AcidsFrench General Practitioners' Attitudes toward Therapeutic Advances in HIV Care: Results of a National SurveySmall dipeptide-based HIV protease inhibitors containing the hydroxymethylcarbonyl isostere as an ideal transition-state mimicLaboratory and clinical markers of HIV infection in a national haemophilia cohort treated with recombinant factor VIII concentrateHIV/AIDS patients' perspectives on adhering to regimens containing protease inhibitorsNutritional Status and Antiprotease TherapyArthralgias and cryoglobulinemia during protease inhibitor therapy in a patient infected with human immunodeficiency virus and hepatitis C virusSaquinavir enhances the mucosal toxicity of infusional cyclophosphamide, doxorubicin, and etoposide in patients with HIV-associated non-Hodgkin's lymphomaVisceral abdominal-fat accumulation associated with use of indinavirAntiretroviral therapy for patients with HIV diseaseCMV Retinitis and the Controversies Associated with Highly Active Antiretroviral Therapy and the Immune Recovery HypothesisA Cellular Anti-Apoptosis Protein is Cleaved by the HIV-1 ProteaseImpact of opportunistic disease on survival in patients with HIV infectionChemotherapy for AIDS-Related LymphomasProtease inhibitor therapy in children with perinatally acquired HIV infectionIn VitroAssays for Activities of Retroviral IntegraseRegression of Cytomegalovirus Retinitis Associated With Protease-inhibitor Treatment in Patients With AIDSAntiretroviral therapies in HIV-1 infectionThe HIV global pandemic: The development and emerging implicationsTuberculosis in the 90'sKinetics Analysis of Consecutive HIV Proteolytic Cleavages of the Gag-Pol PolyproteinSurvival and treatment of AIDS patients 1984-1993: experience of a smaller east London HIV centre.Indinavir NephropathyZur Pharmakologie der Virustatika — eine kurze ÜbersichtAntiretroviral drugs for AIDS 15 June 1996Volume 124, Issue 12Page: 1086-1088KeywordsAntiviralsBlood plasmaDrugsFood and Drug AdministrationHIVHIV infectionsNucleosidesProtease inhibitorsRNAToxicity Issue Published: 15 June 1996 CopyrightCopyright © 1996 by American College of Physicians. All Rights Reserved.PDF DownloadLoading ...